

# **Impact of vaccination on household transmission of SARS-COV-2 in England**

Ross J Harris<sup>1</sup>; Jennifer A Hall<sup>2,3</sup>; Asad Zaidi<sup>2</sup>; Nick J Andrews<sup>1</sup>; J Kevin Dunbar<sup>2\*</sup>; Gavin Dabrera<sup>2\*</sup>

## **Affiliations:**

<sup>1</sup> Statistics, Modelling and Economics Department, Public Health England

<sup>2</sup> COVID-19 National Epidemiology Cell, Public Health England

<sup>3</sup> UCL Institute for Women's Health

\*Equal contribution as senior authors.

Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG

## Introduction

Vaccination against SARS-CoV-2 with either ChAdOx1 nCoV-19, produced by Astra-Zeneca, or BNT162b2, produced by Pfizer, has been shown to produce a robust antibody response (1,2), and is effective in both preventing cases and reducing the severity of COVID-19 in vaccinated individuals(3,4). While fewer cases will reduce disease burden, it is not yet clear whether these vaccinations will also reduce transmission in the minority who have been vaccinated but develop post-vaccination infection.

Vaccination commenced in England in December 2020 targeting priority groups 1 and 2 (Box 1) (those at highest risk of mortality from COVID-19 and frontline health and social care workers) with BNT162b2. Rollout expanded from 4<sup>th</sup> January 2021 with ChAdOx1 nCoV-19, targeting the top four priority groups (Box 1). Fifteen million vaccinations were given to individuals in these groups by 15<sup>th</sup> February 2021, and all individuals in the top nine groups had been offered their first vaccination by 13<sup>th</sup> April 2021(5).

During the second pandemic wave, cases of and deaths from COVID-19 in England peaked in late December 2020 and early January 2021 respectively after the end of November's lockdown measures; the increase in cases in December 2020 also coincided with the emergence of new variants of SARS-CoV-2 such as VOC202012/01(8). The combined effects of a new national lockdown in late December 2020 with school closures and the roll out of the vaccination programme saw cases of and deaths from COVID-19 fall through out January and February 2021, reaching between 3-4000 cases per day by end March 2021 (9).

**Box 1.** Priority groups for vaccination in England(6)

| Priority | Risk group   |
|----------|--|
| 1        | Residents in a care home for older adults and staff working in care homes for older adults   |
| 2        | All those 80 years of age and over and frontline health and social care workers  |
| 3        | All those 75 years of age and over   |
| 4        | All those 70 years of age and over and clinically extremely vulnerable(7) individuals (not including pregnant women and those under 16 years of age) |
| 5        | All those 65 years of age and over   |
| 6        | Adults aged 16 to 65 years in an at-risk group and unpaid carers   |
| 7        | All those 60 years of age and over   |
| 8        | All those 55 years of age and over   |
| 9        | All those 50 years of age and over   |
| 10       | Rest of the population (to be determined)  |

Household contacts of confirmed cases are at high risk of infection and this setting is an important route of transmission overall(10); studies internationally have shown secondary attack rates (SAR) within households vary from 3.9%(11) to 37% (12), depending on the setting, lockdown measure, and methods of ascertaining cases (active versus passive), with an overall secondary attack rate in households estimated at 16.6% in a recent systematic review and meta-analysis(13). Published analysis of passive surveillance data from England shows an average SAR of 5.9% between June and September 2020(14), but this represents the nadir of the epidemic in England and in our routine analyses we have seen the SAR rise above 10% in December 2020.

As a high risk setting for transmission, households can provide early evidence for impacts of interventions, such as vaccines, in preventing the onward transmission from an index case

to household contacts. Although based on a specific setting, this may have implications for transmissibility in other settings, where transmission risks may be similar.

The risk of transmission of SARS-CoV-2 to other people after vaccination can only be studied in the small proportion of individuals who develop infection despite having been vaccinated. The purpose of this study was to determine whether individuals who have received one dose of vaccine but still become infected with SARS-COV-2 up to 60 days after the first dose, are less likely than unvaccinated cases to transmit to their unvaccinated household contacts.

## **Methods**

### *Dataset creation*

The creation of the routine HOSTED dataset has been described in detail elsewhere(14). In brief, laboratory confirmed cases of COVID-19 in England which are reported to national laboratory surveillance systems(15) are linked to individuals who share the same address, using National Health Service (NHS) number and the Unique Property Reference Number (UPRN). Known institutional settings (using UPRN information) such as care homes, prisons, and households with more than 10 residents are excluded.

For this analysis, the HOSTED dataset was linked to data from the National Immunisation Management System (NIMS)(16) to obtain information such as the dates and types of COVID-19 vaccinations for all individuals vaccinated in England.

### *Dataset description*

HOSTED includes individual-level socio-demographic data for cases and household contacts, including age, sex, and Index of Multiple Deprivation (IMD); information on property type, confirmed cases using PCR-based SARS-CoV-2 through national reporting systems, and linked information on hospitalisation and mortality. The vaccination data include date and type (ChAdOx1 nCoV-19 or BNT162b2) of first and second doses for all vaccinated individuals in the HOSTED dataset.

### *Data preparation*

We defined *Index Cases* as the earliest case of laboratory-confirmed COVID-19, by diagnosis date, for a household. *Household Contacts* were defined as all individuals with the same address as the index cases of COVID-19; and *Secondary Cases* as a known household contact of an index case with a positive SARS-CoV-2 test that has a specimen date between two and 14 days after the specimen date of the index case.

The analysis cohort included households with an index case occurring between 4th January 2021 to 28th February 2021, with 14 days observable follow up for all contacts. Households in which *any* individual was vaccinated prior to the 4<sup>th</sup> January were excluded, so that our analysis would be as broadly generalizable as possible to the overall vaccination campaign. Households in which the index case was vaccinated 1-14 days after testing positive for COVID-19 were also excluded, as were all contacts who had been vaccinated prior to the index case testing positive. We excluded index cases tested under 'pillar 1' of the national testing strategy, which is a proxy for a case being either hospitalised or a health worker. This was because the household contacts of hospitalised cases are likely to have differential exposure profiles compared to contacts of non-hospitalised cases. Finally, we restricted analyses to households with a single index case age 16+, and no co-primary cases (any other cases on the same or next day as the index case).

### *Statistical analysis*

We defined *vaccinated* index cases as having been vaccinated 21 days or more prior to testing positive for COVID-19 based on evidence of the time needed for the vaccine to provide a sufficient level of immunity(17). *Non-vaccinated* index cases were defined as not having received a vaccine prior to testing positive. Households where the index case received the vaccine less than 21 days before testing positive were excluded from this analysis.

We compared household contacts of index cases receiving either the ChAdOx1 nCoV-19 or BNT162b2 vaccines, with contacts of unvaccinated index cases, and the proportion of contacts who tested positive within 2-14 days of the index case (*secondary cases*) in each group: unvaccinated (base group), BNT162b2, and ChAdOx1 nCoV-19.

The odds of being a secondary case was modelled using logistic regression, adjusted for the following covariates: age of index case and contact (ages grouped as 0-15, 16-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+), sex of index case and contact, government office region (nine groups), calendar week of index case, index of multiple deprivation quintile (IMD) and household type. Household types were defined as in previous work(14) and further subdivided by size to give the following groups: pairs/couples of adults both age under 65; pairs/couples of adults with one or both 65+; households with children (<16) of size 2-4, 5-7 and 8-10; multi-generational households (at least one adult age 65+ and age gaps of at least 16 years between this adult and two younger household members) of size 3-4, 5-7 and 8-10; and 3+ adult-only households of size 3-4, 5-7 and 8-10.

We used robust standard errors in the final model to allow for dependence between individuals in the same household. Results are presented in terms of odds ratios (ORs) and 95% confidence intervals (CI).

We also conducted a matched case-control study, matching secondary cases and non-cases on the basis of age group and sex of index case and contact, region, week, IMD quintile, and household type. This analysis was intended to ensure balanced covariates in cases and non-cases, as there may be complex inter-relationships between covariates. Odds ratios of infection in the household contacts were estimated using conditional logistic regression.

In addition to a binary exposure (vaccinated 21+ days before becoming an index case vs. unvaccinated) we considered households in which the index case was vaccinated any time up to the date of testing positive, in whom there may be a partial effect on transmission.

Timing of vaccination was grouped in two-to-three day intervals in the 0-24 days prior to testing positive, then at four, five, or more than six weeks prior to testing positive. The odds of being a secondary case according to vaccination timing (vs. unvaccinated index case) was modelled using the same logistic regression model described above and we examined the timing according to age of index case and contact, and calendar time (January and February).

Finally, we compared households in which the index case was vaccinated 21-35 days before testing positive with households in which the index case was vaccinated 1-10 days before testing positive. Three sets of analyses were conducted; a multivariable logistic regression model including the covariates specified above; a matched case-control study; and a stratified cohort study. Matching/stratification was first conducted on age group of index case and contact, plus the week of index case vaccination. The latter was to ensure the groups were comparable in terms of index case vaccination timing, and differed only in the timing of subsequently testing positive. We then added further variables to the stratification/matching: sex of index case and contact, region, IMD quintile, and household type.

## Results

### *Description of the data set*

Data were extracted on 23<sup>rd</sup> March 2021 and included individuals with at least 14 days of observable follow-up from the date of specimen collection from the index case (i.e. index cases between 4th January 2021 to 28th February 2021, secondary cases up to 14<sup>th</sup> March 2021). There were 552,984 residential households of two to 10 people where there was at least one case. Table 1 shows the exclusions applied to arrive at the final analysis cohort.

**Table 1.** Numbers of households, contacts of index cases, and secondary cases in the data, numbers excluded according to different criteria, total exclusions, and final analysis cohort.

|   | <b>Households</b> | <b>Contacts</b> | <b>Secondary cases</b> |
|---|-------------------|-----------------|------------------------|
| <b>Starting cohort</b>                                      | 552,984           | 1,449,427       | 147,109                |
| <b>Exclusions (overlapping criteria)</b>                    |                   |                 |                        |
| Multiple index/co-primary cases                             | 83,960            | 146,193         | 17,944                 |
| Index case age under 16                                     | 23,560            | 69,213          | 8,120                  |
| Index case tested in pillar 1                               | 65,270            | 153,821         | 12,448                 |
| Index case vaccinated prior to 4 <sup>th</sup> January 2020 | 21,475            | 54,904          | 4,991                  |
| Index case vaccinated 2-14 days after testing positive      | 3,849             | 8,283           | 516                    |
| Contacts vaccinated prior to index case date                | 59,161            | 67,622          | 8,152                  |
| <b>Total exclusions (any criteria)</b>                      | <b>211,276</b>    | <b>430,585</b>  | <b>44,447</b>          |



|  |         |           |         |
|--|---------|-----------|---------|
| <b>Households where no remaining contacts after exclusions</b> | 8,435   | 0         | 0       |
| <b>Final cohort</b>  | 365,447 | 1,018,842 | 102,662 |

The exclusion criteria did not overlap substantially, although contacts in households where the index case was vaccinated prior to 4<sup>th</sup> January 2021 were more likely to have been vaccinated (28.6% vs. 3.7%). The final cohort consisted of 365,447 households with a single index case and 1,018,842 contacts. There were 4,107 households where the index case was vaccinated 21 days or more before testing positive (1.12%), and 20,110 where the index case was vaccinated less than 21 days before testing positive (5.51%). Table 2 shows characteristics of contacts according to vaccination status of the index case.

**Table 2.** Characteristics of household contacts according to vaccination status of index case.

|                          | Unvaccinated index case |       | Index case vaccinated 21+ days before +ive |       | Index case vaccinated <21 days before +ive |       |
|--------------------------|-------------------------|-------|--|-------|--|-------|
|                          |                         |       | N  | col % | N  | col % |
|                          | N                       | col % | N  | col % | N  | col % |
| <b>Age of index case</b> |                         |       |  |       |  |       |
| 16-29                    | 302,600                 | 31.5% | 1,750                                      | 18.7% | 9,436                                      | 19.7% |
| 30-39                    | 259,731                 | 27.0% | 2,269                                      | 24.2% | 11,178                                     | 23.3% |
| 40-49                    | 196,898                 | 20.5% | 2,215                                      | 23.7% | 11,277                                     | 23.5% |
| 50-59                    | 138,531                 | 14.4% | 2,074                                      | 22.2% | 9,981                                      | 20.8% |
| 60-69                    | 50,538                  | 5.3%  | 743  | 7.9%  | 4,157                                      | 8.7%  |
| 70-79                    | 10,031                  | 1.0%  | 181  | 1.9%  | 1,289                                      | 2.7%  |
| 80+                      | 2,436                   | 0.3%  | 131  | 1.4%  | 632  | 1.3%  |
| <b>Age of contact</b>    |                         |       |  |       |  |       |

|                        | <b>Index case</b>   |              |                         |              | <b>Index case</b>             |              |
|------------------------|---------------------|--------------|-------------------------|--------------|-------------------------------|--------------|
|                        | <b>Unvaccinated</b> |              | <b>vaccinated 21+</b>   |              | <b>vaccinated &lt;21 days</b> |              |
|                        | <b>index case</b>   |              | <b>days before +ive</b> |              | <b>before +ive</b>            |              |
|                        | <b>N</b>            | <b>col %</b> | <b>N</b>                | <b>col %</b> | <b>N</b>                      | <b>col %</b> |
| 0-15                   | 263,190             | 27.4%        | 2,969                   | 31.7%        | 13,429                        | 28.0%        |
| 16-29                  | 221,231             | 23.0%        | 2,321                   | 24.8%        | 11,630                        | 24.3%        |
| 30-39                  | 141,858             | 14.8%        | 1,216                   | 13.0%        | 6,276                         | 13.1%        |
| 40-49                  | 117,352             | 12.2%        | 965                     | 10.3%        | 5,258                         | 11.0%        |
| 50-59                  | 126,144             | 13.1%        | 1,210                   | 12.9%        | 6,388                         | 13.3%        |
| 60-69                  | 64,166              | 6.7%         | 574                     | 6.1%         | 3,679                         | 7.7%         |
| 70-79                  | 20,388              | 2.1%         | 77                      | 0.8%         | 1,020                         | 2.1%         |
| 80+                    | 6,436               | 0.7%         | 31                      | 0.3%         | 270                           | 0.6%         |
| <b>Sex</b>             |                     |              |                         |              |                               |              |
| Male                   | 503,099             | 52.4%        | 5,776                   | 61.7%        | 28,460                        | 59.4%        |
| Female                 | 457,666             | 47.6%        | 3,587                   | 38.3%        | 19,490                        | 40.6%        |
| <b>Index case date</b> |                     |              |                         |              |                               |              |
| 04 Jan - 10 Jan        | 293,672             | 30.6%        | 0                       | 0.0%         | 1,618                         | 3.4%         |
| 11 Jan - 17 Jan        | 219,283             | 22.8%        | 0                       | 0.0%         | 8,242                         | 17.2%        |
| 18 Jan - 24 Jan        | 151,170             | 15.7%        | 0                       | 0.0%         | 12,180                        | 25.4%        |
| 25 Jan - 31 Jan        | 101,926             | 10.6%        | 334                     | 3.6%         | 10,182                        | 21.2%        |
| 01 Feb - 07 Feb        | 73,531              | 7.7%         | 1,302                   | 13.9%        | 6,908                         | 14.4%        |
| 08 Feb - 14 Feb        | 49,759              | 5.2%         | 2,117                   | 22.6%        | 3,887                         | 8.1%         |
| 15 Feb - 21 Feb        | 42,509              | 4.4%         | 3,004                   | 32.1%        | 2,786                         | 5.8%         |
| 22 Feb - 28 Feb        | 28,915              | 3.0%         | 2,606                   | 27.8%        | 2,147                         | 4.5%         |
| <b>IMD quintile</b>    |                     |              |                         |              |                               |              |
| 1                      | 265,475             | 27.6%        | 2,486                   | 26.6%        | 11,070                        | 23.1%        |
| 2                      | 239,131             | 24.9%        | 2,065                   | 22.1%        | 10,850                        | 22.6%        |
| 3                      | 184,066             | 19.2%        | 1,930                   | 20.6%        | 10,099                        | 21.1%        |
| 4                      | 149,319             | 15.5%        | 1,556                   | 16.6%        | 8,720                         | 18.2%        |
| 5                      | 122,774             | 12.8%        | 1,326                   | 14.2%        | 7,211                         | 15.0%        |

|                             | Unvaccinated |       | Index case vaccinated 21+ |       | Index case vaccinated <21 days |       |
|-----------------------------|--------------|-------|---------------------------|-------|--------------------------------|-------|
|                             | index case   |       | days before +ive          |       | before +ive                    |       |
|                             | N            | col % | N                         | col % | N                              | col % |
| <b>Region</b>               |              |       |                           |       |                                |       |
| East Midlands               | 79,301       | 8.3%  | 1,310                     | 14.0% | 5,180                          | 10.8% |
| East of England             | 102,804      | 10.7% | 931                       | 9.9%  | 5,973                          | 12.5% |
| London                      | 229,362      | 23.9% | 571                       | 6.1%  | 5,442                          | 11.3% |
| North East                  | 32,640       | 3.4%  | 390                       | 4.2%  | 1,795                          | 3.7%  |
| North West                  | 132,466      | 13.8% | 1,730                     | 18.5% | 6,991                          | 14.6% |
| South East                  | 139,455      | 14.5% | 1,156                     | 12.3% | 8,440                          | 17.6% |
| South West                  | 58,015       | 6.0%  | 811                       | 8.7%  | 4,433                          | 9.2%  |
| West Midlands               | 122,359      | 12.7% | 1,594                     | 17.0% | 6,453                          | 13.5% |
| Yorkshire and The<br>Humber | 64,363       | 6.7%  | 870                       | 9.3%  | 3,243                          | 6.8%  |
| <b>Household type</b>       |              |       |                           |       |                                |       |
| Adult pair/couple           | 51,802       | 5.4%  | 733                       | 7.8%  | 3,547                          | 7.4%  |
| Older pair/couple           | 14,006       | 1.5%  | 143                       | 1.5%  | 1,260                          | 2.6%  |
| HH with children, 2-4       | 200,338      | 20.9% | 2,469                     | 26.4% | 11,322                         | 23.6% |
| HH with children, 5-7       | 212,808      | 22.1% | 1,931                     | 20.6% | 8,952                          | 18.7% |
| HH with children, 8-10      | 57,688       | 6.0%  | 314                       | 3.4%  | 1,449                          | 3.0%  |
| Multi-gen HH, 3-4           | 9,876        | 1.0%  | 142                       | 1.5%  | 701                            | 1.5%  |
| Multi-gen HH, 5-7           | 53,814       | 5.6%  | 496                       | 5.3%  | 2,728                          | 5.7%  |
| Multi-gen HH, 8-10          | 31,917       | 3.3%  | 139                       | 1.5%  | 1,137                          | 2.4%  |
| Adult only, 3-4             | 208,556      | 21.7% | 2,264                     | 24.2% | 12,093                         | 25.2% |
| Adult only, 5-7             | 98,479       | 10.3% | 632                       | 6.7%  | 4,158                          | 8.7%  |
| Adult only, 8-10            | 21,481       | 2.2%  | 100                       | 1.1%  | 603                            | 1.3%  |

In all households, the majority of index cases and contacts were age <60, with a high proportion of individuals aged <40 in unvaccinated households. Over half of contacts were

also aged <40 for all household groups. Male contacts were more common in households in which the index case had been vaccinated. As households where the index case had been vaccinated for 21+ days before being infected required a 3-week window, there are no households in this group with an index case between 4<sup>th</sup> – 24<sup>th</sup> January; otherwise, index cases approximately follow the overall case rate, as described above. Distributions of IMD, region and household size were generally similar between the vaccinated and unvaccinated groups.

### *Vaccine effect on transmission*


In households where the index case was not vaccinated before testing positive, there were 96,898 secondary cases out of 960,765 household contacts (10.1%). There were 196 secondary cases in 3,424 contacts (5.72%) where the index case received the ChAdOx1 nCoV-19 vaccine 21 days or more before testing positive, and 371 secondary cases in 5,939 contacts (6.25%) where the index case received the BNT162b2 vaccine 21 days or more before testing positive.

The unadjusted odds ratio for being a secondary case if the index case was vaccinated with ChAdOx1 nCoV-19 21 days or more before testing positive (vs. index case not vaccinated) was 0.55 (95% CI 0.46, 0.67), and for BNT162b2, 0.57 (95% CI 0.49, 0.65). Results from the multivariable model were similar, with an adjusted OR of 0.53 (95% CI 0.43, 0.63) for ChAdOx1 nCoV-19 and 0.51 (95% CI 0.44, 0.59) for BNT162b2. Full results from the multivariable logistic regression model are given in Supplementary Material S1. There was little evidence for effect modification by age of index case (likelihood ratio p-value=0.085) or age of contact (p=0.177). Figure 1 shows estimates for each vaccine according to the age of the index case and age of contact.

In the matched case-control study, 1,513 contacts of index cases vaccinated with ChAdOx1 nCoV-19 (64%) were matched to contacts with unvaccinated index cases, with an estimated OR of infection of 0.62 (95% CI 0.48, 0.79). There were 2,694 contacts of index cases

vaccinated with BNT162b2 (67%) matched to contacts with unvaccinated index cases, with an estimated OR of 0.51 (95% CI 0.42, 0.62).


**Figure 1.** Odds ratios and 95% confidence intervals for contacts becoming a secondary case if the index case was vaccinated with ChAdOx1 nCoV-19 or BNT162b2 21 days or more before testing positive, vs. contacts where the index case was not vaccinated. Results by age of index case and contact from multivariable logistic regression.



### Vaccination timing

Figure 2 shows odds ratios for contacts in which the index case had been vaccinated according to the timing of vaccination, compared to households where the index case was not vaccinated. This analysis also includes households where the index case was vaccinated between 0 and 20 days before testing positive, which due to the timing of the rollout and data under consideration, are a larger group than those vaccinated 21+ days before testing positive.

**Figure 2.** Odds ratios for contacts becoming a secondary case according to vaccination timing of the index case (days before testing positive) by type of vaccination, vs. contacts where the index case was not vaccinated. Results from multivariable logistic regression.



The results show that contacts of vaccinated cases have lower odds of being secondary cases if the index case was vaccinated 14 days or more before testing positive after controlling for calendar week, but this protective effect diminishes sharply if vaccination occurs closer to the positive test date. Of note however is that estimates diverge for the two vaccines: where index cases are recently vaccinated (less than 10 days before testing positive), odds of being a secondary case are lower for ChAdOx1 nCoV-19, but higher for BNT162b2. Supplementary materials S2 show odds ratios of becoming a secondary case according to vaccination timing for different subgroups and time periods, to explore this further. This suggests that odds of transmission were lower in later calendar weeks for index cases receiving either vaccine compared to unvaccinated cases, suggesting an effect of timing as case rates declined. The pattern among recently vaccinated was also seen in the groups of working age (16-39 and 40-59 years) with sparse data for those age over 60.

#### *Estimated effects based on vaccine timing*

Table 3 shows estimated ORs comparing households where the index case was vaccinated 21-35 days before testing positive with households where the index case was vaccinated 1-10 days before testing positive (with the same vaccine type). The adjusted ORs from multivariable logistic regression indicated a halving in the odds of contacts becoming secondary cases if the index case was vaccinated with either ChAdOx1 nCoV-19 or BNT162b2 21-35 days before testing positive. The matched case-control analysis gave slightly attenuated results; as more matching variables were included the estimated effect for ChAdOx1 nCoV-19 became slightly weaker and that for BNT162b2 slightly stronger, but less than half the cases could be matched on the larger set of covariates, and the confidence intervals for ChAdOx1 nCoV-19 were wide. A similar pattern to the results was seen in the stratified cohort analysis; and using the full set of covariates resulted in a very large number of strata (9,825 for ChAdOx1 nCoV-19 and 16,820 for BNT162b2), the majority of which could not be included in the analysis due to there being no secondary cases within the strata.

**Table 3.** Estimated odds ratios for contacts being a secondary case according to vaccination of the index case 21-35 vs. 1-10 days before the index case tested positive; multivariable logistic regression, matched case-control and stratified cohort designs. The *N* column is the sample size, except for the matched case-control, which is the number of matched secondary cases. The percentage is the proportion of all available data that could be used in the model (either matched, or having usable strata).

|  | Vaccine         | OR (95% CI)       | N or cases | % of data |
|--|-----------------|-------------------|------------|-----------|
| <b>Logistic regression</b>                                       |                 |                   |            |           |
|  | ChAdOx1 nCoV-19 | 0.53 (0.44, 0.63) | 13169      | 100.0%    |
|  | BNT162b2        | 0.49 (0.44, 0.56) | 25688      | 100.0%    |
| <b>Matched case-control</b>                                      |                 |                   |            |           |
| 1: Age of index case and contact, week of index case vaccination | ChAdOx1 nCoV-19 | 0.57 (0.46, 0.70) | 1218       | 99.4%     |
|  | BNT162b2        | 0.55 (0.48, 0.64) | 2930       | 99.8%     |
| 2: as (1) plus: Sex of index case and contact                    | ChAdOx1 nCoV-19 | 0.56 (0.45, 0.70) | 1194       | 97.5%     |
|  | BNT162b2        | 0.56 (0.48, 0.64) | 2909       | 99.0%     |
| 3: as (2) plus: household type                                   | ChAdOx1 nCoV-19 | 0.57 (0.45, 0.71) | 1032       | 84.2%     |
|  | BNT162b2        | 0.50 (0.42, 0.58) | 2705       | 92.1%     |



|  |                     |                      | N or  |           |
|--|---------------------|----------------------|-------|-----------|
|  | Vaccine             | OR (95% CI)          | cases | % of data |
| 4: <i>as (3) plus</i> : IMD  | ChAdOx1 nCoV-<br>19 | 0.53 (0.41,<br>0.69) | 767   | 62.6%     |
|  | BNT162b2            | 0.50 (0.42,<br>0.59) | 2264  | 77.1%     |
| 5: <i>as (3) plus</i> : region   | ChAdOx1 nCoV-<br>19 | 0.65 (0.49,<br>0.87) | 668   | 54.5%     |
|  | BNT162b2            | 0.49 (0.41,<br>0.59) | 1992  | 67.8%     |
| 5: <i>as (3) plus</i> : region and IMD                                 | ChAdOx1 nCoV-<br>19 | 0.67 (0.46,<br>0.99) | 386   | 31.5%     |
|  | BNT162b2            | 0.45 (0.35,<br>0.58) | 1239  | 42.2%     |
| <b>Stratified cohort</b>   |                     |                      |       |           |
| 1: Age of index case and<br>contact, week of index case<br>vaccination | ChAdOx1 nCoV-<br>19 | 0.55 (0.46,<br>0.65) | 12296 | 93.4%     |
|  | BNT162b2            | 0.52 (0.46,<br>0.58) | 24937 | 97.1%     |
| 2: <i>as (1) plus</i> : Sex of index<br>case and contact               | ChAdOx1 nCoV-<br>19 | 0.55 (0.46,<br>0.66) | 10397 | 79.0%     |
|  | BNT162b2            | 0.51 (0.45,<br>0.58) | 22843 | 88.9%     |
| 3: <i>as (2) plus</i> : household type                                 | ChAdOx1 nCoV-<br>19 | 0.52 (0.43,<br>0.63) | 6755  | 51.3%     |
|  | BNT162b2            | 0.50 (0.44,<br>0.57) | 17453 | 67.9%     |
| 4: <i>as (3) plus</i> : IMD  | ChAdOx1 nCoV-<br>19 | 0.54 (0.43,<br>0.68) | 3362  | 25.5%     |

|                                       | Vaccine         | OR (95% CI)       | N or cases | % of data |
|---------------------------------------|-----------------|-------------------|------------|-----------|
| <i>5: as (3) plus: region</i>         |                 | 0.49 (0.42,       |            |           |
|                                       | BNT162b2        | 0.57)             | 10808      | 42.1%     |
|                                       | ChAdOx1 nCoV-19 | 0.62 (0.48, 0.80) | 2565       | 19.5%     |
|                                       | BNT162b2        | 0.47 (0.40, 0.55) | 8783       | 34.2%     |
| <i>5: as (3) plus: region and IMD</i> | ChAdOx1 nCoV-19 | 0.77 (0.53, 1.12) | 1044       | 7.9%      |
|                                       |                 | 0.43 (0.35,       |            |           |
|                                       | BNT162b2        | 0.55)             | 3841       | 15.0%     |

## Discussion

These results show that the likelihood of household transmission is 40-50% lower for households in which the index cases are vaccinated 21 days or more prior to testing positive (compared to no vaccination), with similar effects for both ChAdOx1 nCoV-19 and BNT162b2 vaccines. Results persisted after adjustment for measured covariates. This effect on onward transmission in the household was particularly apparent for index cases aged less than 70 years. A matched case-control analysis also demonstrated similarly reduced odds ratios for secondary infections in household contacts.

The results on timing of vaccination indicate that the reduction in transmission can be detected at 14 days after vaccination, which is consistent with the timing of effective protection from infection for the vaccinated individual (18).

We used a definition of vaccination status of the index case as having been vaccinated 21 days or more prior to testing, as a summary measure for both vaccines. Three different analytical approaches (logistic regression, matched case-control and stratified cohort) compared index cases vaccinated 21-35 days before a positive test with index cases vaccinated 1-10 days before positive test; all three methods showed reductions in transmission for vaccination 21-35 days before a positive test with both vaccines in keeping with their previous ORs. These results lend confidence to the overall conclusion that vaccination reduces transmission, as the comparison is restricted to index cases that have received a particular vaccine, varying only in the timing of vaccination before testing positive.

To understand observed differences between BNT162b2 and ChAdOx1 nCoV-19 in proportions of secondary cases for index cases who became cases within a week of vaccination, further analysis by age of index case, and contact, calendar week of positive test in index case and vaccination (Supplementary Material S2) suggests underlying differences in the groups, which are not accounted for by measured covariates or differences in the vaccine. This is consistent with reported initial administration in social care workers

focusing on BNT162b2 (17) and the early phase of the study period being influenced by high case rates.

These findings provide emerging evidence that receipt of at least one dose of either vaccine reduces transmission of SARS-CoV-2 from a diagnosed case to other persons in the household setting. Currently there is limited published evidence available; Shah *et al* reported reduced risks of infection in household contacts of healthcare workers who received the same vaccines in Scotland (19). However, this study was limited to index cases of working age, specifically health-care workers who may have a different risk of exposure, whereas the analysis presented here represents a wider cross-section of the population who received these vaccines. Therefore, our study can be considered to demonstrate the wider impacts of the vaccination programme in the community, to include those who were vaccinated due to older age and underlying conditions.

Most of the vaccinated index cases (93%) in our analysis had received just one dose of vaccine and it will be important to assess if there are any further reduction in transmissibility from receiving a second dose of vaccine when such data become available. Further comparisons will also be made to other surveillance data on household transmission, such as the HOCO study (20).

### *Limitations*

The HOSTED dataset only has information on diagnosed secondary cases; studies with active follow-up and serological testing have shown higher rates of household transmission (21). Our data cannot identify asymptomatic cases. However, case ascertainment is unlikely to be biased towards either the contacts of vaccinated or unvaccinated cases. Additionally, differences in transmission according to the timing of vaccination in index cases, and comparison of vaccination more versus less than three weeks before testing positive in index cases lends confidence to the overall results. It is reassuring that a similar effect was observed in a different dataset (19).

Our definition of 'secondary' cases may have led to the inclusion of some cases that were in fact co-primary. As the incubation period for SAR-CoV2 is thought to be two-to-14 days (22,23), we chose a threshold of two days between the specimen dates of the index and secondary cases to offset the risks of misclassifying cases as either co-primary or as secondary. Previous sensitivity analyses using a cut-off of four days found little effect on results or on the multivariable model (24). We have also made the implicit assumption that two (or more) cases occurring in a household within two-to-14 days represents household transmission when it is also plausible that they are two independent community acquired infections. However, the data from this analysis refer to a time in which England was in lockdown and therefore the scope for acquiring infection outside the household should be reduced.

We restricted our analysis to household contacts of index cases who tested positive through community testing (pillar 2), whereas individuals tested in pillar 1 consist of those tested in hospital and healthcare workers. Hospitalised cases may present markedly different exposure risks to their household contacts: severe cases may be more infectious; however, once hospitalised, their contacts would not be exposed to further risk of infection. Data on hospitalisation is currently limited in this dataset due to reporting delays and because hospitalisation is only recorded in the HOSTED dataset if it occurs on or after the positive test date. It is not currently possible to specifically identify healthcare workers in Pillar 1 case data, to aid further characterisation. Further work is required to understand the exposure risks for contacts of cases tested in pillar 1, and how these may be affected by vaccination.

Although the main group receiving vaccinations in the time period was the over 70s, the number of index cases in this age group was small, and vaccinated index cases aged 70+ smaller still, due to the effectiveness of the vaccines. Further, household contacts aged 70+ who have not received the vaccination, when the index case has been vaccinated, are also comparatively rare, due to the success of the vaccine rollout programme. These analyses are thus based largely on individuals aged less than 60, who will have been vaccinated due

to underlying health conditions, being carers of vulnerable individuals, or because they are social care workers. Again, doubts around the comparability of vaccinated and unvaccinated index cases are assuaged by the results on the timing of vaccination in vaccinated individuals. These findings are likely to be generalisable to other high income countries using these two vaccines in national vaccination programmes.

## Conclusions

In addition to the direct effects of preventing cases and reducing severity, we have shown that both the ChAdOx1 nCoV-19 and BNT162b2 vaccines are associated with reduced likelihood of household transmission by 40-50% from individuals diagnosed with COVID-19 after vaccination, highlighting important wider benefits to close contacts. While this analysis was primarily intended to understand impacts on transmission to household contacts rather than those outside the household, the former are consistently identified as being at high risk for secondary infection. Therefore, these results could also have implications for transmissibility in other settings with similar transmission risks. These would need to be considered in future pandemic modelling to fully capture the impact of the vaccination programme and to inform public health strategies and public communication going forward.

## References

1. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*. 2020 Aug;396(10249):467–78.
2. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*. 2020 Oct 22;586(7830):594–9.
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020 Dec 31;383(27):2603–15.
4. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in

- older adults in England [Internet]. Infectious Diseases (except HIV/AIDS); 2021 Mar [cited 2021 Apr 2]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.03.01.21252652>
5. Coronavirus (COVID-19) in the UK: People vaccinated [Internet]. 2021. Available from: <https://coronavirus.data.gov.uk/details/vaccinations>
  6. Public Health England. COVID-19 vaccination first phase priority groups [Internet]. 2021 [cited 2021 Apr 10]. Available from: <https://www.gov.uk/government/publications/covid-19-vaccination-care-home-and-healthcare-settings-posters/covid-19-vaccination-first-phase-priority-groups>
  7. Department of Health and Social Care. Definition of clinically extremely vulnerable groups [Internet]. 2021. Available from: <https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19#cev>
  8. Public Health England. Investigation of novel SARS-CoV-2 variant of Concern 202012/01 Technical briefing 2 [Internet]. 2020. Available from: <https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201>
  9. COVID-19: reported SARS-CoV-2 deaths in England [Internet]. Public Health England; Available from: <https://www.gov.uk/government/publications/covid-19-reported-sars-cov-2-deaths-in-england>
  10. Haroon S, Chandan JS, Middleton J, Cheng KK. Covid-19: breaking the chain of household transmission. *BMJ*. 2020 14;370:m3181.
  11. Draper AD, Dempsey KE, Boyd RH, Childs EM, Black HM, Francis LA, et al. The first 2 months of COVID-19 contact tracing in the Northern Territory of Australia, March-April 2020. *Commun Dis Intell* 2018. 2020 Jul 2;44.
  12. Boddington NL, Charlett A, Elgohari S, Byers C, Coughlan L, Vilaplana TG, et al. Epidemiological and clinical characteristics of early COVID-19 cases, United Kingdom of Great Britain and Northern Ireland. *Bull World Health Organ*. 2021 Mar 1;99(3):178–89.
  13. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020 01;3(12):e2031756.
  14. Hall JA, Harris RJ, Zaidi A, Woodhall SC, Dabrera G, Dunbar JK. HOSTED—England's Household Transmission Evaluation Dataset: preliminary findings from a novel passive surveillance system of COVID-19. *Int J Epidemiol*. 2021 Apr 9;dyab057.
  15. Clare T, Twohig KA, O'Connell A-M, Dabrera G. Timeliness and completeness of laboratory-based surveillance of COVID-19 cases in England. *Public Health*. 2021 Apr;S0033350621001219.
  16. NHS Digital. The National Immunisation Management Service. [Internet]. 2021. Available from: <https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/>

17. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). SSRN Electron J [Internet]. 2021 [cited 2021 Apr 2]; Available from: <https://www.ssrn.com/abstract=3790399>
18. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2021 Feb 17;NEJMc2036242.
19. V Shah AS, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households [Internet]. *Public and Global Health*; 2021 Mar [cited 2021 Apr 2]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.03.11.21253275>
20. COVID-19: vaccine surveillance strategy. [Internet]. Public Health England; 2021. Available from: <https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-strategy>
21. SARS-CoV2 susceptibility and transmission in children: evidence from PHE systems (S0717) - 19 August 2020. Public Health England, 2020. [Internet]. Public Health England; 2020. Available from: <https://www.gov.uk/government/publications/phe-sars-cov2-susceptibility-and-transmission-risk-in-children-an-overview-of-current-evidence-from-phe-surveillance-work-19-august-2020>
22. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2020;25(5).
23. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med*. 2020 Feb 17;9(2).
24. Hall J, Harris R, Zaidi A, Woodhall S, Dabrera G, Dunbar J. HOSTED—England’s Household Transmission Evaluation Dataset: preliminary findings from a novel passive surveillance system of COVID-19. *Int J Epidemiol*. 2021;(In press).

## **Ethics approval**

The HOSTED surveillance system was reviewed and approved by the PHE Research Ethics Governance Group. The data was collected and linked by NHS Digital. The data was processed lawfully under GDPR Article 6(1)e and 9(2)i and shared under Regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002.



## **Funding**

This work was undertaken as part of the core functions of Public Health England in relation to the surveillance of communicable diseases and outbreak response.

## **Data Availability Statement**

The data underlying this article cannot be shared publicly due to the legal and policy controls placed on data used as part of the government's response to the Covid19 pandemic.

## **Acknowledgements**

The authors wish to thank Heather Pinches, Phillip Bowker and Paul Ellingham as well as the rest of the NHS Digital team whose hard work and dedication enabled the creation of these data during the UK Covid19 pandemic response; and Jemma Walker for comments on an early version of this manuscript.

## **Conflict of interest statement**

None declared

## Supplementary material S1 – Multivariable logistic regression for outcome of household contact becoming a secondary case



|                          | Odds Ratio | LCI  | UCI  | p-value |
|--------------------------|------------|------|------|---------|
| <b>Age of index case</b> |            |      |      |         |
| 16-29                    | 1 (base)   |      |      |         |
| 30-39                    | 1.33       | 1.30 | 1.37 | <0.001  |
| 40-49                    | 1.72       | 1.68 | 1.77 | <0.001  |
| 50-59                    | 1.98       | 1.93 | 2.04 | <0.001  |
| 60-69                    | 2.09       | 2.01 | 2.16 | <0.001  |
| 70-79                    | 2.00       | 1.86 | 2.14 | <0.001  |
| 80+                      | 2.00       | 1.75 | 2.28 | <0.001  |
| <b>Age of contact</b>    |            |      |      |         |
| 0-15                     | 1 (base)   |      |      |         |
| 16-29                    | 1.67       | 1.63 | 1.71 | <0.001  |
| 30-39                    | 1.76       | 1.72 | 1.81 | <0.001  |
| 40-49                    | 2.13       | 2.08 | 2.18 | <0.001  |
| 50-59                    | 2.45       | 2.38 | 2.51 | <0.001  |
| 60-69                    | 2.21       | 2.14 | 2.29 | <0.001  |
| 70-79                    | 1.82       | 1.73 | 1.92 | <0.001  |
| 80+                      | 1.67       | 1.54 | 1.82 | <0.001  |
| <b>Sex of index case</b> |            |      |      |         |
| Male                     | 1 (base)   |      |      |         |
| Female                   | 0.99       | 0.97 | 1.01 | 0.175   |
| <b>Sex of contact</b>    |            |      |      |         |
| Male                     | 1 (base)   |      |      |         |
| Female                   | 1.27       | 1.25 | 1.28 | <0.001  |
| <b>Index case date</b>   |            |      |      |         |
| 04 Jan - 10 Jan          | 1 (base)   |      |      |         |
| 11 Jan - 17 Jan          | 0.93       | 0.91 | 0.96 | <0.001  |



|                             | Odds Ratio | LCI  | UCI  | p-value |
|-----------------------------|------------|------|------|---------|
| 18 Jan - 24 Jan             | 0.87       | 0.85 | 0.89 | <0.001  |
| 25 Jan - 31 Jan             | 0.82       | 0.80 | 0.85 | <0.001  |
| 01 Feb - 07 Feb             | 0.85       | 0.82 | 0.88 | <0.001  |
| 08 Feb - 14 Feb             | 0.90       | 0.86 | 0.93 | <0.001  |
| 15 Feb - 21 Feb             | 0.83       | 0.79 | 0.87 | <0.001  |
| 22 Feb - 28 Feb             | 0.76       | 0.72 | 0.81 | <0.001  |
| <b>IMD quintile</b>         |            |      |      |         |
| 1                           | 1 (base)   |      |      |         |
| 2                           | 1.06       | 1.03 | 1.09 | <0.001  |
| 3                           | 1.12       | 1.09 | 1.15 | <0.001  |
| 4                           | 1.19       | 1.16 | 1.22 | <0.001  |
| 5                           | 1.18       | 1.15 | 1.22 | <0.001  |
| <b>Region</b>               |            |      |      |         |
| East Midlands               | 1.09       | 1.05 | 1.13 | <0.001  |
| East of England             | 1.04       | 1.01 | 1.08 | 0.023   |
| London                      | 0.78       | 0.76 | 0.80 | <0.001  |
| North East                  | 1.24       | 1.18 | 1.30 | <0.001  |
| North West                  | 1.13       | 1.10 | 1.17 | <0.001  |
| South East                  | 1 (base)   |      |      |         |
| South West                  | 0.95       | 0.91 | 0.99 | 0.020   |
| West Midlands               | 1.14       | 1.10 | 1.18 | <0.001  |
| Yorkshire and The<br>Humber | 1.14       | 1.09 | 1.18 | <0.001  |
| <b>Household type</b>       |            |      |      |         |
| Adult pair/couple           | 1 (base)   |      |      |         |
| Older pair/couple           | 1.04       | 0.98 | 1.10 | 0.171   |
| HH with children, 2-4       | 1.21       | 1.17 | 1.25 | <0.001  |
| HH with children, 5-7       | 0.79       | 0.76 | 0.81 | <0.001  |
| HH with children, 8-10      | 0.48       | 0.45 | 0.51 | <0.001  |

|                             | Odds Ratio | LCI  | UCI  | p-value |
|-----------------------------|------------|------|------|---------|
| Multi-gen HH, 3-4           | 0.79       | 0.73 | 0.86 | <0.001  |
| Multi-gen HH, 5-7           | 0.71       | 0.68 | 0.75 | <0.001  |
| Multi-gen HH, 8-10          | 0.54       | 0.51 | 0.58 | <0.001  |
| Adult only, 3-4             | 0.72       | 0.70 | 0.74 | <0.001  |
| Adult only, 5-7             | 0.53       | 0.51 | 0.55 | <0.001  |
| Adult only, 8-10            | 0.25       | 0.22 | 0.28 | <0.001  |
| <b>Vaccination of index</b> |            |      |      |         |
| <b>case</b>                 |            |      |      |         |
| Not vaccinated              | 1 (base)   |      |      |         |
| ChAdOx1 nCoV-19             | 0.52       | 0.43 | 0.62 | <0.001  |
| BNT162b2                    | 0.54       | 0.47 | 0.62 | <0.001  |

## Supplementary Material S2

The following plots show odds ratios for contacts becoming a secondary case according to vaccination timing of the index case (days before testing positive) by type of vaccination, vs. contacts where the index case was not vaccinated as in Figure 1 of the main paper. Plots are by different subgroups, with results from the multivariable logistic regression model used in the main paper, stratified by various subgroups.





Note: the comparison group, unvaccinated index cases, do not have a vaccination date; therefore a comparable date for grouping was imputed based on the average interval between vaccination and testing positive in vaccinated index cases, which was calculated separately for each week of vaccination.